Eddie Hickman
Stock Analyst at Guggenheim
(3.15)
# 1,133
Out of 4,876 analysts
16
Total ratings
43.75%
Success rate
5.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $78 → $84 | $40.29 | +108.51% | 8 | May 2, 2025 | |
| PMN ProMIS Neurosciences | Reiterates: Buy | $6 | $0.48 | +1,137.37% | 2 | Apr 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $9.28 | +137.07% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $12.40 | +158.06% | 1 | Mar 13, 2025 | |
| CYBN Cybin | Initiates: Buy | $35 | $8.58 | +307.93% | 1 | Mar 13, 2025 | |
| OTLK Outlook Therapeutics | Reiterates: Buy | $12 | $1.75 | +585.71% | 3 | Jan 17, 2025 |
Tarsus Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $78 → $84
Current: $40.29
Upside: +108.51%
ProMIS Neurosciences
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.48
Upside: +1,137.37%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $9.28
Upside: +137.07%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $12.40
Upside: +158.06%
Cybin
Mar 13, 2025
Initiates: Buy
Price Target: $35
Current: $8.58
Upside: +307.93%
Outlook Therapeutics
Jan 17, 2025
Reiterates: Buy
Price Target: $12
Current: $1.75
Upside: +585.71%